lung-cancer

Documents about lung-cancer

• Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors#140996ClinicalTrials.gov
• Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.#290998ClinicalTrials.gov
• The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person#311141ClinicalTrials.gov
• Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer#343849ClinicalTrials.gov
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer#238105ClinicalTrials.gov
• Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC#253010ClinicalTrials.gov
• Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients#272331ClinicalTrials.gov
• Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC#321712ClinicalTrials.gov
• ITIL-168 in Advanced Solid Tumors#325305ClinicalTrials.gov
• Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance#373614ClinicalTrials.gov
• PD-L1 Expression in Cancer (PECan Study).#394763ClinicalTrials.gov
• Popova2026_Functional_Precision_Oncology_Lung_Cancer_Nanoliter_Droplet_Array#206559Radar OAI Repository
• Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management.#122805NCBI PubMed Central
• Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA#123456ClinicalTrials.gov
• Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.#143554ClinicalTrials.gov
• Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma#261498ClinicalTrials.gov
• Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial#279489ClinicalTrials.gov
• Decision-making processes among patients with lung cancer considering participation in neoadjuvant immunotherapy clinical trials: A qualitative grounded theory study#205425Europe PMC
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer#411409ClinicalTrials.gov
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer#6868OpenAlex
• Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer#148566ClinicalTrials.gov
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer#217013ClinicalTrials.gov
• Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study#174879ClinicalTrials.gov
• Regulation of the ERK-MAPK signaling by the small GTPase RHOB in a cell model of non-small cell lung cancer#238940HAL (France)
• PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1#136340ClinicalTrials.gov
• Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer#162469ClinicalTrials.gov
• First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy#172301ClinicalTrials.gov
• Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis#215395HAL (France)
• Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)#230397ClinicalTrials.gov
• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer#267994ClinicalTrials.gov
• TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy#314343ClinicalTrials.gov
• VSV-02 Compassionate Use in Advanced Solid Tumors#230415ClinicalTrials.gov
• Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.#154873ClinicalTrials.gov
• Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath#272444ClinicalTrials.gov
• Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC#141019ClinicalTrials.gov
• Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC#172287ClinicalTrials.gov
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC#172320ClinicalTrials.gov
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC#314317ClinicalTrials.gov
• Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations#314339ClinicalTrials.gov
• Cancer-associated fibroblasts in the lung cancer microenvironment from multi-dimensional mechanisms to therapeutic strategies.#433985NCBI PubMed Central
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy#332762ClinicalTrials.gov
• NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial#172314ClinicalTrials.gov
• Lung Cancer Screening and Interception: Innovative Approaches for Enduring Challenges#132995PMC Full-Text (OAI)
• Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.#159822NCBI PubMed Central
• NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy#181769ClinicalTrials.gov
• Circulating DNA in Surgically Treated NSCLC#184844ClinicalTrials.gov
• 95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment#226124ClinicalTrials.gov
• Durvalumab as Consolidation for Patients LS-SCLC#279513ClinicalTrials.gov
• State Cigarette Taxes and Lung Cancer Incidence, United States, 1970-2019.#371628NCBI PubMed Central
• Essential Components for the Development of an Early Lung Cancer Detection Program#388566NCBI Bookshelf